EA202091500A1 - Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa - Google Patents

Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa

Info

Publication number
EA202091500A1
EA202091500A1 EA202091500A EA202091500A EA202091500A1 EA 202091500 A1 EA202091500 A1 EA 202091500A1 EA 202091500 A EA202091500 A EA 202091500A EA 202091500 A EA202091500 A EA 202091500A EA 202091500 A1 EA202091500 A1 EA 202091500A1
Authority
EA
Eurasian Patent Office
Prior art keywords
carbamoylcyclohexyl
pyrazole
acids
bonded
lpa antagonists
Prior art date
Application number
EA202091500A
Other languages
English (en)
Inventor
Янь Ши
Питер Тай Вах Ченг
Йинь Ван
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA202091500A1 publication Critical patent/EA202091500A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I)или его стереоизомеру, таутомеру или фармацевтически приемлемой соли или сольвату, где все переменные определены в настоящем документе. Эти соединения являются селективными ингибиторами рецептора LPA.
EA202091500A 2017-12-19 2018-12-18 Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa EA202091500A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607541P 2017-12-19 2017-12-19
PCT/US2018/066110 WO2019126085A1 (en) 2017-12-19 2018-12-18 Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Publications (1)

Publication Number Publication Date
EA202091500A1 true EA202091500A1 (ru) 2020-09-14

Family

ID=65003575

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091500A EA202091500A1 (ru) 2017-12-19 2018-12-18 Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa

Country Status (14)

Country Link
US (1) US11384067B2 (ru)
EP (1) EP3728216B1 (ru)
JP (1) JP7301839B2 (ru)
KR (1) KR102698386B1 (ru)
CN (1) CN111699180A (ru)
AU (1) AU2018388482A1 (ru)
BR (1) BR112020011953A2 (ru)
CA (1) CA3085347A1 (ru)
EA (1) EA202091500A1 (ru)
ES (1) ES2962367T3 (ru)
IL (1) IL275361A (ru)
MX (1) MX2020005874A (ru)
SG (1) SG11202005701VA (ru)
WO (1) WO2019126085A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP3728210A1 (en) * 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN113366000A (zh) * 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022174882A1 (en) * 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
CN117295717A (zh) * 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
CA3238094A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
CN117024409A (zh) * 2023-10-10 2023-11-10 药康众拓(北京)医药科技有限公司 氘代lpa1抑制剂化合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4396808B2 (ja) 2001-02-08 2010-01-13 小野薬品工業株式会社 Ｌｐａ受容体調節剤からなる泌尿器疾患治療剤
US7432271B2 (en) * 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
JP2014508111A (ja) 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
CA2869541A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as lpar antagonists
CA2869564A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-aryltriazole compounds as lpar antagonists
EA201492283A1 (ru) * 2012-06-20 2015-04-30 Ф. Хоффманн-Ля Рош Аг Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
KR102090231B1 (ko) * 2013-03-15 2020-03-17 에피젠 바이오싸이언시즈, 아이엔씨. 질환의 치료에 유용한 헤테로환식 화합물
US20170283400A1 (en) * 2014-09-17 2017-10-05 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
JP7212047B2 (ja) * 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
EP3728240B1 (en) * 2017-12-19 2022-06-29 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112189010A (zh) 2017-12-19 2021-01-05 百时美施贵宝公司 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸
US11261174B2 (en) * 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists

Also Published As

Publication number Publication date
JP7301839B2 (ja) 2023-07-03
KR20200100712A (ko) 2020-08-26
EP3728216A1 (en) 2020-10-28
MX2020005874A (es) 2020-08-13
WO2019126085A1 (en) 2019-06-27
BR112020011953A2 (pt) 2020-11-17
US20210087173A1 (en) 2021-03-25
KR102698386B1 (ko) 2024-08-22
IL275361A (en) 2020-07-30
US11384067B2 (en) 2022-07-12
EP3728216B1 (en) 2023-09-06
CN111699180A (zh) 2020-09-22
JP2021507895A (ja) 2021-02-25
AU2018388482A1 (en) 2020-07-30
ES2962367T3 (es) 2024-03-18
SG11202005701VA (en) 2020-07-29
CA3085347A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
EA202091500A1 (ru) Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
PH12017502082A1 (en) Antifungal compounds
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
EA201691302A1 (ru) Новые гетероциклические соединения
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
EA201891615A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201792021A1 (ru) Ингибитор jak
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA202091472A1 (ru) Триазол-азины циклогексиловой кислоты как антагонисты lpa
EA201791596A1 (ru) Пиразоловые соединения
MX2018010652A (es) Composiciones farmaceuticas.
AR125853A2 (es) Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico
SA119400353B1 (ar) مشتق بيرازول مستبدل